Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years

Osteoporosis International

Volumn 7, Issue 2, 1997, Pages 119-125

  Adami, S ^a   Bufalino, L ^b   Cervetti, R ^c   Di Marco, C ^d   Di Munno, O ^e   Fantasia, L ^f   Isaia, G C ^g   Serni, U ^h   Vecchiet, L ⁱ   Passeri, M ^j,k   Castiglione, G N ^b   Gardini, F ^b   Letizia, G ^d   Occhipinti, L ^e   Pardini, N ^e   Agamennone, M ^f   Sciolla, A ^g   Matucci, A ^h   Riboldi, R ⁱ   Costi, D ^j   Dall'Aglio, E ^j   Pedrazzoni, M ^j   more..

^a UNIVERSITY OF VERONA   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF PISA   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h IOT   (Italy)

ⁱ UNIVERSITY OF CHIETI   (Italy)

^j UNIVERSITY OF PARMA   (Italy)

^k MAGGIORE HOSPITAL   (Italy)

more..

Author keywords

Ipriflavone; Postmenopausal bone loss; Radial bone mineral density

Indexed keywords

AGENTS AFFECTING METABOLISM; CALCIUM; CALCIUM LACTOGLUCONATE; CREATININE; HYDROXYPROLINE; IPRIFLAVONE;

ADULT; ARTICLE; ASTHENIA; BONE ATROPHY; BONE MASS; BONE METABOLISM; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DROWSINESS; FEMALE; FOREARM; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROXYPROLINE URINE LEVEL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; PRURITUS; RADIUS; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO;

EID: 8244245268     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01623686     Document Type: Article

References (44)

1. Consensus Development Conference. Who are candidates for preventive and therapeutic therapy for osteoporosis? 1996 World Congress on Osteoporosis, Amsterdam, 18-23 May. Osteoporosis Int 1997;1:1-7.
2. Cummings SR, Black DR, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
3. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33
4. Jensen KS, Mosekilde L, Mosekilde L. A model of vertebral trabecular bone architecture and its mechanical properties. Bone 1990;11:417-23.
5. Cecchini MG, Mühlbauer RC, Fleisch H. Ipriflavone inhibits bone resorption in rats, effect of experimental conditions [abstract]. Osteoporosis Int 1996;6(Suppl 1):317.
6. Reginster JY. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993;23:223-32
7. Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, et al. Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 1991;6:987-96.
8. Cheng S, Zhang S, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 1994;55:356-62.
9. Mazzuoli GF, Romagnoli E, Carnevale V, Scarda A, Scarnecchia L, Pacitti MT, et al. Effects of ipriflavone on bone remodeling in patients with primary hyperparathyroidism. Bone Miner 1992;19(Suppl 1):S27-33.
10. Agnusdei D, Camporeale A, Gonneili S, Gennari C, Baroni MC, Passen M. Short term treatment of Paget's disease of bone with ipriflavone. Bone Miner 1992;19(Suppl 1):S35-42.
11. Valente M, Bufalino L, Castiglione GN, D'Angelo R, Mancuso A, Galoppi P, Zichella L. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54:377-80
12. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, et al. Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 1992;51:82-91.
13. Passen M, Biondi M, Costi D, Dall'Aglio E, Pedrazzoni M, Bufalino L, et al. Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Miner Electrolyte Metab 1995;9:137-44.
14. Maugeri D, Panebianco P, Russo MS, Motta M, Tropea S, Motta L, et al. Ipriflavone treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 1994;19:253-63.
15. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, et al. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocr Invest 1993;16:333-7.
16. Gambacciani M, Spinetti A, Piaggesi L, Cappagli B, Taponeco F, Manetti P. et al. Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists. Bone Miner 1994;26:19-26.
17. Rondelli I, Acerbi D, Ventura P. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure. Int J Clin Pharm Res 1991;11:183-92.
18. Gillings D, Koch G. The application of the principle of intention-to-treat analysis of clinical trials. Drug Inform J 1991;25:411-24.
19. Matthews JNS, Altman DG, Campbell MJ, Tayston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
20. European Agency for the evaluation of Medicinal Products. CPMP/175/95: Note for guidance on the procedure for competent authorities on the undertaking of pharmacovigilance. 1995.
21. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990;323:878-83.
22. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
23. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
24. Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;37:649-55.
25. Agnusdei D, Gennari C, Bufalino L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and a new, non-hormonal, bone active drus. Osteoporosis Int 1995;5:462-6.
26. Agnusdei D, Gennari C, Bufalino L. Effects of ipriflavone on vertebral bone mass and bone turnover in postmenopausal women with osteopenia [abstract]. Bone 1995;16(Suppl):122S.
27. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55:82-6.
28. Hasling C, Charles P, Tagehoj Jensen F, Mosekilde L. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis. Osteoporosis Int 1994;4:191-203.
29. Storm T, Thamsborg G, Steiniche T, Genant HK, Helmer Sorensen O. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;18:1265-71.
30. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluonde for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994;4:76-83.
31. Meschia M, Brincat M, Barbacini P, Crossignani PG, Albisetti W. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20.
32. Overgaard K, Riis BJ. Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int 1994;55:79-81.
33. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980;II:1151-3.
34. Marx CW, Dailey GE III, Cheney C, Vint VC II, Muchmore DB. Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Miner Res 1992;11:1275-9.
35. Passen M. Effect of 3-year treatment with ipriflavone on peripheral bone mass in postmenopausal women [abstract]. Osteoporosis Int 1996;6(Suppl. 1):239.
36. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report 843. Geneva: WHO, 1994.
37. Nilas L, Gotfredesen A, Riis BJ, Christiansen C. The diagnostic validity of local and total bone mineral measurements in postmenopausal osteoporosis and osteoarthritis. Clin Endocrinol (Oxf) 1986;25:711-20.
38. Adami S, Ortolani S, Wasnich R. Evaluation of therapeutic efficacy in osteoporosis. Osteoporosis Int 1995;5:75-8.
39. Riggs BL, Hodgson SF, O'Fallon WM. Effects of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
40. Ghezzo C, Cadel S, Borelli G, Maiorino M, Civitelli R, Bufalino L, Bongrani S. Ipriflavone does not alter bone apatite crystal structure in adult male rats. Calcif Tissue Int 1996;59:496-499.
41. Civitelli R, Abbasi-Jahromi SH, Halstead LR, Dimaragonas A. Ipriflavone improves bone density and biochemical properties of adult male rat bones. Calcif Tissue Int 1995;56:215-9.
42. Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M. Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci 1986;38:951-8.
43. Yamazaki I. Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci 1986;38:757-64.
44. Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 1992;15:755-61.